Shield Therapeutics - Focus on increasing US market access
Shield Therapeutics’ (STX) value stems from Accrufer’s US market opportunity as the company seeks to maximise returns through...
662 Views
Shield Therapeutics - Operating results eclipsed by financing difficulties
Shield Therapeutics reported FY21 results in line with market expectations, recording revenue of £1.5m, including a maiden £0.1m contribution from...
669 Views
Shield Therapeutics - 2021 focus on Accrufer
Shield Therapeutics (STX) successfully launched its key asset, Accrufer (oral ferric maltol for iron deficiency), in the US market on 1 July, in...
618 Views
Shield Therapeutics - Greg Madison succeeds Tim Watts as CEO
Shield Therapeutics (STX) has announced the appointment of a new chief executive officer (CEO), Greg Madison, with effect from 1 June 2021. Greg is...
578 Views
Shield Therapeutics - US partner next major inflection point
Shield Therapeutics’ (STX’s) interim results highlight the progress made year to date. Re-analysis of the Feraccru/Accrufer AEGIS-H2H data show it...
73 Views